ABSTRACT
Asthma is the most common chronic respiratory condition of childhood worldwide, with around 14% of children and young people affected. Despite the high prevalence, paediatric asthma outcomes are inadequate, and there are several avoidable deaths each year. Characteristic asthma features include wheeze, shortness of breath and cough, which are typically triggered by a number of possible stimuli. There are several diagnostic challenges, and as a result, both overdiagnosis and undertreatment of paediatric asthma remain problematic. Effective asthma management involves a holistic approach addressing both pharmacological and non-pharmacological management, as well as education and self-management aspects. Working in partnership with children and families is key in promoting good outcomes. Education on how to take treatment effectively, trigger avoidance, modifiable risk factors and actions to take during acute attacks via personalised asthma action plans is essential. This review aimed to provide an overview of good clinical practice in the diagnosis and management of paediatric asthma. We discuss the current diagnostic challenges and predictors of life-threatening attacks. Additionally, we outline the similarities and differences in global paediatric asthma guidelines and highlight potential future developments in care. It is hoped that this review will be useful for healthcare providers working in a range of child health settings.

INTRODUCTION
Asthma is a chronic respiratory disease characterised by episodes of wheeze, cough, and shortness of breath. Around 14% of children worldwide have a diagnosis of asthma, making it the most common chronic respiratory disease of childhood.1

Poor asthma control is associated with a number of negative effects on children and families. For example, they are more likely to be absent from school, have additional educational needs and have lower educational attainment.2 Caregivers also experience missed work days and financial challenges as a result.3 Some children will experience severe symptoms and life-threatening attacks.4

Taking the UK as an example, paediatric asthma outcomes are poor overall with considerable associated morbidity and high rates of emergency hospital admissions, and most pertinently, there are several preventable deaths each year.5 Alarmingly, the National Review of Asthma Deaths (NRAD) found that in almost all paediatric cases, there were a number of significant avoidable contributing factors and that these deaths may have been preventable.6

There are several factors that make the diagnosis and management of asthma in children challenging. The aim of this review was to explore these issues and highlight good clinical practice in the diagnosis and management of paediatric asthma.

PRESENTATION OF ASTHMA
Children with asthma typically present with a symptom triad of wheeze, shortness of breath and cough. However, ‘asthma’ is an umbrella term used to describe this collection of symptoms and, when present, should prompt practitioners to ask, ‘What type of asthma is this?’ There are a number of asthma subtypes that present and respond to treatment differently. Identification of the features of asthma and modifiable or treatable traits should only be the start of the diagnostic journey.7 Asthma symptoms are normally intermittent in nature and may not be present at the time of clinical review, making the diagnosis challenging in some cases.8 Additionally, disease phenotypes are not fixed and may evolve over time, necessitating ongoing review of symptoms and treatment.9
Wheeze is a key feature of asthma and, if not present, a diagnosis of asthma in a child is unlikely. Wheeze is an expiratory high-pitched whistle that occurs as a result of inflammation and narrowing of the small airways. Parental understanding of wheeze varies, and clarifying what is meant when it is reported is key in making an accurate diagnosis.

The prevalence of ‘preschool wheeze’ is an additional challenge when diagnosing asthma in young children. In the first few years of life, many children will experience wheeze, but not all will go on to develop true asthma. The diagnosis of asthma should therefore be reviewed routinely to identify true asthma and alter treatment where necessary. Favourable response to an appropriate trial of asthma treatment is an important confirmatory piece of diagnostic evidence.

Clinical examination may be normal in children and adolescents with asthma if they present during asymptomatic periods. During acute attacks, use of accessory muscles of respiration and widespread wheeze may be present. Chest hyperinflation may be identified in acute and chronic disease settings.

### ASThma TRIGGERS

Asthma attacks commonly occur following exposure to one or several triggers. Viral respiratory infections remain the leading cause, but there are a number of other known triggers (Box 1), including allergens, secondhand smoke exposure, or changes in ambient air temperature or humidity. Identification and documentation of specific asthma triggers should be part of routine care. Education on trigger recognition and avoidance is essential.

### RISK FACTORS FOR ASThMA

There are a number of risk factors that should be explored in the history of children who present with features of asthma. In symptomatic children, a personal or family history of atopic features, including asthma, eczema or rhinitis, supports a diagnosis of asthma. Some additional risk factors are outlined in Box 2. Education on modifiable risk factors, for example, exposure to secondhand smoke or air pollution and obesity, should be delivered routinely during consultations and asthma reviews.

### PAEDIATRIC ASTHMA PHENOTYPES

Asthma is a heterogeneous disease in which there are several phenotypes and underlying endotypes. Phenotypes are subtypes of asthma that share clinical characteristics such as symptom triggers, atopic features, disease severity and response to treatment. Endotypes are subtypes of asthma that are characterised by similar underlying biological mechanisms.

Key endotypes include ‘type 2-high’ and ‘type 2-low’ asthma. Identifying asthma phenotypes and endotypes can facilitate targeted treatment based on the pathophysiology occurring in a specific individual. For example, allergic or eosinophilic asthma that frequently starts in childhood is type 2-high and is characterised by eosinophilic airway inflammation, raised IgE and fractional exhaled nitric oxide (FeNO) levels. Typically, type 2-high asthma responds well to inhaled corticosteroid (ICS) treatment. A number of biologic agents can be used in the management of asthma, under specialist supervision, and their use varies on asthma endotypes (Table 8).

### DIFFERENTIAL DIAGNOSES AND DIAGNOSTIC UNCERTAINTY

Misdiagnosis of asthma remains a major problem with rates of both underdiagnosis and overdiagnosis being high. Overdiagnosis is problematic as it exposes children to unnecessary side effects of medications and runs the risk of trivialising asthma.

There are several conditions that may be associated with chronic cough, wheeze and/or shortness of breath in children and therefore present similarly to asthma (Table 1). Due to the difficulties with diagnosis, especially in young children where objective testing is not possible, the diagnosis of asthma should be reviewed at each clinical presentation and interaction.

---

**Box 1 Common asthma triggers**

- Viral respiratory tract infections
- Exercise
- Weather changes in temperature and humidity
- Domestic pollutants (eg, pests, mould and dust mites)
- Environmental pollutants (eg, air pollution)
- Secondhand smoke exposure
- Pets and animals
- Strong odours
- Anxiety or strong emotions
- Drugs (eg, non-steroidal anti-inflammatory drugs and beta blockers)
- Gastro-oesophageal reflux

**Box 2 Asthma risk factors**

- Personal or family history of atopy: eczema, allergic rhinitis or nasal polyposis
- Family history of asthma
- Exposure to secondhand smoke
- Preterm birth
- Low birth weight
- Obesity
- Poor housing quality/mould and dampness
- Air pollution
- Allergic or eosinophilic asthma that frequently starts in childhood is type 2-high and is characterised by eosinophilic airway inflammation, raised IgE and fractional exhaled nitric oxide (FeNO) levels.
diagnosis challenging. Most diagnoses are made in primary care where there is often limited access to objective testing at present. Despite guideline recommendations, objective testing is frequently only available in secondary or tertiary care settings where equipment and trained staff are available. The COVID-19 pandemic has served to exacerbate these issues and increase backlogs. Various solutions have been proposed, including community diagnostic hubs. In some healthcare systems, the cost of undergoing objective testing is a cause of health inequalities.

Additionally, the symptom onset for most cases of paediatric asthma occurs before the age of 3 years, when lung function testing cannot be used to aid diagnosis. In this age group, response to an asthma treatment trial is useful to aid diagnostic decision making and is recommended in a number of national guidelines.

**MANAGEMENT OF ASTHMA IN CHILDREN**

The management of asthma is multifactorial, and to optimise disease control, a number of pharmacological, non-pharmacological and self-management aspects need to be considered.

**Pharmacological management**

The pharmacological management of asthma involves two key components: maintenance and reliever therapies. Maintenance therapies are the mainstay of asthma management, and the treatment aim is that no reliever therapies are required. Use of reliever therapy suggests asthma control is poor.

An overview of maintenance and reliever therapies is outlined in tables 3 and 4, respectively. A stepwise approach to asthma management is encouraged, and pharmacological management varies on age, symptom control and the national guideline used. An overview of
### Table 2: Summary of paediatric asthma national guidelines: focusing on diagnosis

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Year</th>
<th>Diagnostic criteria</th>
<th>Recommended objective testing</th>
<th>When to refer to a specialist</th>
<th>When to consider alternative diagnoses</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NICE Guidelines (UK)</strong></td>
<td>2017</td>
<td>Under 5 years: findings in clinical history and examination that are suggestive of asthma</td>
<td>Over 5 years: Spirometry and bronchodilator reversibility or FeNO first line, Additional tests, PEF, bronchial challenge test with histamine or methacholine</td>
<td>Children who are not responding to treatment and/or cannot complete objective testing</td>
<td>When children have symptoms of asthma but normal objective testing results</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Over 5 years: findings in clinical history and examination that are suggestive of asthma and either spirometry demonstrating obstructive airflow and bronchodilator reversibility or a FeNO level of 35 ppb or more</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Global Initiative for Asthma (global)</strong></td>
<td>2021</td>
<td>6 years and over: findings in clinical history that are suggestive of asthma plus evidence of variability in expiratory airflow limitation with either spirometry and bronchodilator reversibility, repeated PEF measurements, positive exercise challenge or positive bronchial challenge</td>
<td>6 years and over: either spirometry, PEF, exercise challenge or bronchial challenge to detect variability in lung function</td>
<td>Diagnostic uncertainty, previous life-threatening attack, no/ poor response to asthma treatment</td>
<td>Atypical asthma features, atypical clinical examination findings, for example, cardiac murmurs</td>
</tr>
<tr>
<td><strong>Canadian Thoracic Society (Canada)</strong></td>
<td>2021</td>
<td>Aged 1–5 years: more than one presentation of asthma-like symptoms plus a response to asthma treatment trial</td>
<td>Over 6 years: spirometry and bronchodilator reversibility (first line) additional tests that may be useful: peak flow variability, bronchial challenge and exercise challenge</td>
<td>Diagnostic uncertainty, severe asthma, previous life-threatening attack, need for allergy testing, any hospitalisation as a result of asthma</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Over 6 years: findings in clinical history that are suggestive of asthma plus spirometry showing obstructive expiration and demonstration of reversibility of airflow limitation of at least 12%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>National Asthma Council Australia (Australia)</strong></td>
<td>2021</td>
<td>Aged 1–5 years: findings in clinical history and examination that are suggestive of asthma plus spirometry demonstrating obstructive airflow and bronchodilator reversibility or a FeNO level of 35 ppb or more</td>
<td></td>
<td>When child has characteristic asthma symptoms and diagnosis is not clear from objective testing results</td>
<td>Atypical asthma features No response to treatment trials Results of objective testing do not suggest asthma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6 years and over: findings in clinical history and examination that are suggestive of asthma plus spirometry demonstrating obstructive airflow and bronchodilator reversibility or a FeNO level of 35 ppb or more</td>
<td></td>
<td>When there is no response to asthma treatment trials and/or there is diagnostic uncertainty</td>
<td></td>
</tr>
<tr>
<td><strong>ARF NZ (New Zealand)</strong></td>
<td>2020</td>
<td>Aged 1–11: findings in clinical history that are suggestive of asthma plus a response to asthma treatment trial</td>
<td>Aged 5–11 years: Spirometry should be considered if asthma symptoms are atypical or in those with typical asthma symptoms that do not respond to a treatment trial.</td>
<td>When there is no response to asthma treatment trials and/or there is diagnostic uncertainty</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Aged 1–5 years: findings in clinical history and examination that are suggestive of asthma plus spirometry demonstrating obstructive airflow and bronchodilator reversibility or a FeNO level of 35 ppb or more</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Continued
management approach in a number of national guidelines is summarised in table 5.

GINA guidelines recommend dual ICS and short-acting beta-2 agonist (SABA) therapy to children over the age of 5. SABA monotherapy was previously the main management starting point; however, compared with combined treatment, SABA monotherapy has been shown to be associated with asthma mortality. SABA monotherapy is now only recommended by GINA for use in children aged 5 or less. As seen in table 5, GINA recommends symptom-driven ICS use, compared with daily ICS use, as initial therapy in children over 6 years of age.
Single maintenance and reliever therapy (SMART) inhalers are combined inhalers offering both maintenance and reliever therapy in those with asthma. These inhalers contain a number of maintenance and reliever therapies in different combinations. The use of these inhalers has been shown to reduce the risk of asthma attacks and emergency department (ED) admissions, improve lung function and decrease the need for reliever therapy. There is limited evidence in the effectiveness of SMART inhalers in children, but children over 12 years may be prescribed a SMART inhaler, which acts as both a maintenance and reliever therapy, if symptoms are not well controlled.

There are a number of biologic agents (table 6) that may be used in the management of paediatric asthma. These are endotype-specific, targeted therapies that should be used only under the supervision of specialists. Their availability and cost vary between countries and different healthcare systems. Detailed appraisal of the evidence base for their use is provided in the individual management guidelines and has been recently reviewed.

Non-pharmacological management

Non-pharmacological aspects of asthma management include providing education on modifiable risk factors and comorbidities to caregivers and conducting annual asthma reviews to assess control and future risk.

Education is key to improving caregiver and child understanding of asthma and its management. Clear information regarding modifiable risk factors, such as smoke exposure, domestic pollutants and obesity, should be given. Short-term educational interventions aimed to improve self-management have been shown to increase

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Maintenance therapies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maintenance therapies</td>
<td>Comments</td>
</tr>
<tr>
<td>ICS</td>
<td>Currently used as a first-line maintenance agent in a number of national guidelines; when using ICS, the lowest possible dose to effectively control symptoms should be used to prevent possible adverse effects of growth retardation and risk of adrenal suppression.</td>
</tr>
<tr>
<td>LABA</td>
<td>Used as an add-on therapy when dual ICS and SABA therapy is ineffective. In comparison to SABA, bronchodilation duration is prolonged to 12 hours.</td>
</tr>
<tr>
<td>Leucotriene receptor antagonists (eg, montelukast)</td>
<td>Used as an add-on therapy in those who have poor symptom control despite ICS and LABA treatments. There have been a number of concerns raised regarding possible adverse reactions to montelukast. These include neuropsychiatric features ranging from poor sleep to suicidal ideation.</td>
</tr>
<tr>
<td>Long-acting muscarinic antagonists (eg, tiotropium)</td>
<td>Used as an add-on therapy in those who have poor symptoms control despite ICS and LABA therapies</td>
</tr>
<tr>
<td>Oral theophylline</td>
<td>Used as an add-on therapy, usually in those with uncontrolled symptoms despite several maintenance and reliever therapies Monitoring of plasma level required on initiation of treatment and dose changes</td>
</tr>
<tr>
<td>Biologics</td>
<td>Use as an add-on therapy, under specialist care, in those who have poorly controlled symptoms despite being on several maintenance and reliever therapies. A number of biologic agents are available (table 6). Various individual biologics have been shown to reduce attacks, improve lung function and reduce oral corticosteroid use.</td>
</tr>
</tbody>
</table>

ICS, inhaled corticosteroid; LABA, long-acting beta-2 agonists; SABA, short-acting beta-2 agonist.

<table>
<thead>
<tr>
<th>Table 4</th>
<th>Reliever therapies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reliever therapies</td>
<td>Comments</td>
</tr>
<tr>
<td>SABAs</td>
<td>Currently used as a first-line reliever agent in a number of national guidelines; effects of bronchodilation last for up to 4 hours. SABAs work by rapidly relaxing the smooth muscle of small airways, providing quick relief from asthma symptoms. Should be delivered via an age-appropriate spacer device or only if requiring supplemental oxygen via a nebuliser; older children may be able to use a handheld device without a spacer if trained and deemed competent in using it effectively.</td>
</tr>
<tr>
<td>Oral corticosteroids</td>
<td>Used as a short-term therapy during asthma attacks to reduce airway inflammation and ease symptoms; repeated short-term courses of oral steroids suggest poor chronic symptom control and should trigger a review of maintenance therapy.</td>
</tr>
</tbody>
</table>

SABA, short-acting beta-2 agonist.
### Table 5  Summary of paediatric asthma national guidelines: focusing on management

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Year</th>
<th>First-line management</th>
<th>Add-on therapies*</th>
<th>Treatment withdrawal</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Aged 5–16 years: SABA monotherapy</td>
<td>Aged 5–16 years: second line: low-dose ICS, third line: low-dose ICS and LTRA, fourth line: low-dose ICS and LABA; fifth line: high-dose ICS and LABA; sixth line: referral for specialist management</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Age 6 and over: second line: medium-dose ICS or low-dose ICE and LTRA, fourth line: refer for expert advice</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Age 6–11 years: second line: low-dose ICS; third line: low-dose ICS and LABA or medium-dose ICS or daily SMART combined ICS/LABA; refer for expert advice; fourth line: refer for phenotype assessment</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Adolescents: second line: low-dose ICS; third line: medium-dose ICS; fourth line: medium-dose/high-dose ICS±LABA; refer for phenotype assessment</td>
<td></td>
</tr>
<tr>
<td><strong>GINA (global)20</strong></td>
<td>2021</td>
<td>5 years and under: SABA monotherapy 6–11 years: combined low-dose ICS+SABA (as needed) Adolescents: combined low-dose ICS+SABA</td>
<td>5 years and under: second line: low-dose ICS, third line: medium-dose ICS or low-dose ICE and LTRA, fourth line: refer for expert advice</td>
<td>Stepping down treatment should be considered when both asthma symptoms and lung function have been stable for a period of 3 months or more.</td>
</tr>
<tr>
<td><strong>Canadian Thoracic Society (Canada)32</strong></td>
<td>2021</td>
<td>Aged 1–5 years: SABA monotherapy</td>
<td>Aged 1–5 years: second line: ICS and LTRA, third line: high-dose ICS and LTRA, fourth line: referral for specialist management</td>
<td>After asthma has been well controlled for a period of 3–6 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Aged 6–11: SABA monotherapy</td>
<td>Aged 6–11: second line: ICS and LTRA; third line: high-dose ICS and LTRA; fourth line: high-dose ICS, LTRA and LABA; fifth line: high-dose ICS, LTRA, LABA and oral steroids</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Age 12+: SABA monotherapy</td>
<td>Age 12+: second line: ICS and LTRA; third line: ICS, LTRA and LABA; fourth line: high-dose ICS, LTRA, LABA and tiotropium</td>
<td></td>
</tr>
<tr>
<td><strong>National Asthma Council Australia30</strong></td>
<td>2021</td>
<td>Aged 1–5 years: SABA monotherapy</td>
<td>Aged 1–5 years: second line: low-dose ICS or LTRA; third line: low-dose ICS and LTRA; fourth line: referral for specialist management</td>
<td>Step-down of treatment should be considered when symptoms have been well controlled for a period of at least 6 months.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Aged six and over: SABA monotherapy</td>
<td>Age 6 and over: second line: low-dose ICS or LTRA; third line: low-dose ICS and LTRA or high-dose ICS or ICS/LABA combination; fourth line: referral for specialist management</td>
<td></td>
</tr>
<tr>
<td><strong>Asthma and Respiratory Foundation NZ (New Zealand)31</strong></td>
<td>2020</td>
<td>Aged 1–4 years: SABA and low-dose ICS</td>
<td>Aged 1–4 years: second line: low-dose ICS and LTRA, third line: referral for specialist management</td>
<td>If the child has been stable for 3 months or more on treatment, step-down with an incremental approach.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Aged 5–11 ICS SABA monotherapy</td>
<td>Aged 5–11 years: second line: SABA and low-dose ICS; third line: LABA and low-dose ICS; fourth line: LABA, high dose ICS, LTRA and referral for specialist management</td>
<td></td>
</tr>
<tr>
<td><strong>Irish College of General Practitioners (Ireland)30</strong></td>
<td>2020</td>
<td>Aged 6–11: ICS and SABA (ICS only to be taken when SABA is used as a reliever) Adolescents: ICS and SABA (ICS only to be taken when SABA is used as a reliever)</td>
<td>Aged 6–11: second line: low-dose ICS or LTRA (if ICS is not appropriate); third line: low-dose ICS and LABA or high dose ICS; fourth line: medium-dose ICS, LABA and referral to paediatrics for management advice; fifth line: refer to paediatrics for phenotype assessment</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Adolescents: second line: low-dose ICS; third line: low-dose ICS and LABA; fourth line: medium-dose ICS and LABA or low dose ICS, LABA and LAMA; fifth line: refer to paediatrics for phenotype assessment</td>
<td></td>
</tr>
<tr>
<td><strong>The Japanese Society of Allergology (Japan)27</strong></td>
<td>2020</td>
<td>Aged 1–5 years: SABA monotherapy</td>
<td>Aged 1–5 years: second line: low-dose ICS or LTRA or disodium cromoglycate, third line: medium-dose ICS, fourth line: high dose ICS and LTRA</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Aged 6–15 years: SABA monotherapy</td>
<td>Age 6–15 years: second line: low-dose ICS or LTRA, third line: medium-dose ICS or combined low-dose ICS/LABA, fourth line: high-dose ICS or combined medium dose ICS/LABA</td>
<td></td>
</tr>
</tbody>
</table>

*Continued*
medication adherence,38 improve symptom control and reduce mortality.39

All young people with asthma should have asthma reviews at least annually. These reviews should focus on current symptom control and management, previous attacks, triggers, modifiable risk factors and personal asthma action plans (PAAPs). Asthma reviews are opportunities to assess child and caregiver understanding of asthma and provide education, if necessary. Annual asthma reviews are also opportunities to assess inhaler technique (including spacer use) and provide education on this if necessary. Poor inhaler technique is common in young people with asthma40 and associated with poor disease control.41

Taking time to understand the perceptions of young people and their caregivers in relation to their asthma diagnosis and management is important, and exploring such perceptions may enhance engagement during consultations, subsequently improving outcomes for young people.42

### Self-management

Self-management aspects of paediatric asthma management include asthma education and PAAPs. PAAPs are written documents that are given to young people and/or caregivers that advise them on day-to-day asthma management and what to do in the event of an attack.43 Action plans should be created with patient/caregiver input, shared with relevant individuals (eg, school teachers) and should be reviewed and updated regularly. PAAPs have been shown to reduce ED attendance and missed school days and to increase caregiver confidence when managing attacks.44 The 2018 Annual Asthma Survey found that over 50% of children with asthma in the UK had no PAAP, and around 20% of caregivers did not seek medical advice during acute asthma attacks, highlighting large gaps in education.45

Diet and exercise are additional important self-management aspects within paediatric asthma care. A number of short-term exercise interventions have demonstrated improvements in lung function and symptom control.46 Healthy eating interventions can help reduce body mass index and improve the quality of life of both young people and their caregivers.47

### Withdrawing management/stepping down

Asthma control should be reviewed at every medical contact. When asthma symptoms are well controlled on

---

**Table 5 Continued**

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Year</th>
<th>First-line management</th>
<th>Add-on therapies*</th>
<th>Treatment withdrawal</th>
</tr>
</thead>
<tbody>
<tr>
<td>International Consensus on Paediatric Asthma (global)</td>
<td>2015</td>
<td>Quotes GINA and NICE guidelines</td>
<td>Quotes GINA and NICE guidelines</td>
<td></td>
</tr>
<tr>
<td>GEMA (Spain)24</td>
<td>2009</td>
<td>Age 3 and under: SABA monotherapy</td>
<td>Age 3 and under: second line: low-dose ICS or LTRA; third line: moderate-dose ICS or low-dose ICS and LTRA; fourth line: moderate-dose ICS and LTRA; fifth line: high-dose ICS and LTRA; consider adding LABA; sixth line: oral steroids</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Age 3 and over: SABA monotherapy</td>
<td>Age 3 and under: second line: low-dose ICS or LTRA; third line: moderate-dose ICS or low-dose ICS and LTRA or low dose ICS and LABA; fourth line: moderate-dose ICS and LTRA or moderate-dose ICS and LABA; fifth line: high-dose ICS and LABA; consider adding LTRA and theophyllines; sixth line: consider oral steroids and omalizumab</td>
<td></td>
</tr>
<tr>
<td>Ministry of Health (Singapore)26</td>
<td>2008</td>
<td>No stepwise approach outlined</td>
<td>No stepwise approach outlined</td>
<td>Consider stepping down treatment when symptoms are stable for 3–6 months considering the child’s risk of poor outcomes. Do not stop ICS.</td>
</tr>
<tr>
<td>South African Thoracic Society (South Africa)27</td>
<td>2007</td>
<td>Adolescents: SABA +low-dose ICS</td>
<td>Adolescents: second line: LABA and ICS; third line: LABA, low-dose ICS and LTRA/LABA or high dose ICS or LABA, low dose ICS and theophyllines. Consider oral corticosteroids; fourth line: referral to specialist</td>
<td></td>
</tr>
</tbody>
</table>

*SABA reliever therapy as required at any stage.
GINA, Global Initiative for Asthma; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; LTRA, leucotriene receptor antagonist; NICE, National Institute for Health and Care Excellence; SABA, short-acting beta agonist; SMART, single maintenance and reliever therapy.
<table>
<thead>
<tr>
<th>Biologic</th>
<th>Route and frequency</th>
<th>Mechanism of action</th>
<th>Effect on asthma symptoms*</th>
<th>Effect on attacks and mortality*</th>
<th>Safety concerns/common adverse reactions*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omalizumab</td>
<td>Subcutaneous injection every 4 weeks</td>
<td>IgG1γ antibody that binds to the Fc portion of IgE, resulting in the inability of IgE to bind to the IgE receptor on mast cells. This reduces the concentration of free circulating IgE and consequently mast cell degranulation.</td>
<td>Improved asthma symptoms</td>
<td>Reduced asthma attacks</td>
<td>Mild injection site reactions, headache, fever, abdominal pain, gastroenteritis and nasopharyngitis</td>
</tr>
<tr>
<td>Dupilumab</td>
<td>Subcutaneous injection every 2 weeks</td>
<td>Binds to alpha component of IL-4 receptor blocking IL-4 and IL-13 stimulation of B-cells</td>
<td>Improved asthma symptoms and quality of life</td>
<td>Reduced asthma attacks</td>
<td>Mild injection site reactions and eosinophilia</td>
</tr>
<tr>
<td>Mepolizumab</td>
<td>Subcutaneous injection every 4 weeks</td>
<td>Binds to IL-5 cytokines resulting in reduced peripheral eosinophilia and reduced airway inflammation</td>
<td>Improved asthma symptoms and quality of life</td>
<td>Reduced asthma attacks</td>
<td>Headache, attack of asthma symptoms and bronchitis</td>
</tr>
<tr>
<td>Reslizumab</td>
<td>Intravenous infusion every 4 weeks</td>
<td>Binds to IL-5 cytokines, resulting in reduced peripheral eosinophilia and reduced airway inflammation</td>
<td>Improved asthma symptoms and quality of life</td>
<td>Reduced asthma attacks</td>
<td>Attack of asthma symptoms, nasopharyngitis and upper respiratory tract infections</td>
</tr>
<tr>
<td>Benralizumab</td>
<td>Subcutaneous injection every 4 weeks for the first three doses and then every 8 weeks</td>
<td>Binds to alpha component of IL-5 receptor, resulting in reduced eosinophil activation from IL-5</td>
<td>Improved asthma symptoms and quality of life</td>
<td>Reduced asthma attacks</td>
<td>Headache, sinusitis, nasopharyngitis and fever</td>
</tr>
</tbody>
</table>

*Detailed appraisal of the evidence base for their use is provided in the individual management guidelines and has been recently reviewed.17 **IL, interleukin.
pharmacological therapy, stopping or stepping down medication should be considered to protect young people from unnecessary adverse effects.

The GINA 2021 guidelines advise that clinicians should consider stepping down asthma management to the lowest effective treatment regimen when good symptom control has been achieved for at least 3 months.20 When stepping down treatment, an individualised risk–benefit approach should be taken with focus on the child’s medical history, including frequency of oral corticosteroid use, frequency of asthma attacks, and previous intensive or high-dependency care admissions.46

WHEN TO REFER TO A SPECIALIST
Most paediatric asthma cases are diagnosed in primary care without the input of general paediatricians or paediatric respiratory physicians.6 However, a number of children with asthma may need to be referred to specialists for diagnostic or management input. Common indications for specialist referral include no or poor response to asthma treatments, inconclusive objective testing, poor symptom control with appropriate treatment, frequent oral corticosteroid use or the occurrence of a severe asthma attack.20 27 30 31 49 50 A key element of specialist care is a multidisciplinary team consisting of a number of professionals, including specialist nurses, psychologists, physiologists and pharmacists. Healthcare professionals must consider any safeguarding implications at all paediatric asthma reviews as part of delivering holistic care. Unexplained or frequent ‘do not attend’ appointments or suspicion of poor medical management at home should be flagged and acted on locally.

PREDICTORS OF LIFE-THREATENING ATTACKS
The following features have been shown to increase the likelihood of future severe attacks, and particular attention should be given to these factors during asthma reviews:

1. Previous attack. The strongest risk factor for a future asthma attack is a personal history of a previous attack. One large systematic review and meta-analysis found that children with a recent history of ED attendance with an asthma attack were up to 5.8 times more likely to have another ED attendance and up to three times more likely to be admitted to the hospital with a future asthma attack.31

2. Frequent SABA use and prescription requests. Frequent use of SABA reliever therapy suggests poor control of asthma symptoms. If asthma symptoms are well controlled, no more than two SABA inhalers should be required annually.50 The UK NRAD found that excess SABA prescription and use were prominent in individuals who died of asthma attacks. For those with data available, around 40% had been prescribed 12 or more SABA inhalers in the 12 months before death.6

POSTATTACK REVIEW
Asthma attacks should be viewed as never events. It is essential that a postattack review is conducted to review asthma maintenance treatment, as this is likely to be suboptimal. Failure to review patients post attack, and to alter treatment where appropriate, is likely to predispose to future attacks, which could be life-threatening. Management of the current attack should be reviewed to ensure treatment is appropriate and symptoms are resolving. Some individuals may require additional courses of oral corticosteroids to settle symptoms.7

Current NICE quality standards (UK) state that all individuals hospitalised with an asthma attack should receive a follow-up review in primary care within two working days of discharge,39 to review maintenance management and ensure resolution of symptoms. However, the 2018 National Asthma Survey completed in the UK found that 64% of respondents had no primary care follow-up post attack, and most patients were not aware that this was required.45

Salbutamol weaning
Salbutamol weaning plans are commonly used by a number of healthcare organisations following discharge after an asthma attack. These plans direct caregivers to provide regular SABA therapy, often in a reducing regime, in the days following discharge. There have been a number of concerns raised with regard to these plans with some believing that providing regular SABA therapy may potentially mask deterioration and could delay caregivers seeking medical advice.53 Healthcare professionals should enquire about salbutamol weaning plans during postattack reviews and urge caregivers to seek medical advice if they have concerns or the effects of SABA are not lasting the 4 hours of duration.

FUTURE DEVELOPMENTS IN CARE
The management of paediatric asthma is changing over time with, just as two examples, developments in technology and service structure:

1. Technology. The growing use of technology in asthma care has huge potential to improve clinical outcomes. Smartphone applications can be used to provide medication reminders to users, and this has been shown to increase ICS adherence.54 Applications can also be used to provide educational content to young people and caregivers,35 as well as store PAAPs.56 ‘Smart’ inhalers, not to be confused with SMART inhalers, are devices that can provide audio reminders to users and record when they are used. One paediatric study found that the use of smart inhalers increased treatment adherence to 84%, compared with 30% in the control group.57
2. Diagnostic hubs. In the UK, regional diagnostic hubs for asthma care have been recommended in NHS England’s Long Term Plan. Implementation of diagnostic hubs is hoped to result in earlier and more accurate asthma diagnoses by improving access to objective testing and specialised interpretation. Hubs are designed to improve asthma outcomes by enabling more appropriate treatment initiation and monitoring. There is currently no evidence in the literature of the clinical effects of diagnostic hubs being used in the management of paediatric asthma.

CONCLUSIONS
Paediatric asthma outcomes are currently poor and many deaths are preventable. The aim should be to avoid asthma attacks occurring with appropriate maintenance therapy, and they should be viewed as never events. In order to improve outcomes, accurate diagnosis and management are essential. Good asthma care extends beyond providing medication and should include education, as well as supported self-management advice. The use of PAAPs remains limited and a significant number of young people with asthma do not have one. Postattack asthma reviews are a key opportunity to review maintenance medication and current symptom control.

Contributors All authors conceived the ideas for the article. JM wrote the first draft that was then commented on by JT and MB.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests MB received investigator-led research grants from Pfizer and Roche Diagnostics; speaker fees paid to Newcastle University from Novartis, Roche Diagnostics and TEVA; and travel expenses to educational meetings Boehringer Ingelheim and Vertex Pharmaceuticals.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Malcolm Brodlie http://orcid.org/0000-0003-4591-8299

REFERENCES
6 Physicians RCo. The national review of asthma deaths (NRAstD, 2014.
8 McCormack MC, Enright PL. Making the diagnosis of asthma. Respir Care 2008;53:583–90.


